Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMX-0407 in Previously Treated Unresectable Solid Tumours
NCT05826600Phase 2Terminated
- Sponsor
- iOmx Therapeutics
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of OMX-0407 in solid tumor, sponsored by iOmx Therapeutics. Started Mar 2023; status: terminated.
02
Drugs
OMX-0407
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05826600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826600.